11/14
11:03 am
acrv
Rating for ACRV
Low
Report
Rating for ACRV
11/14
11:03 am
acrv
Rating for ACRV
Low
Report
Rating for ACRV
11/14
08:15 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Medium
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
9/16
10:09 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
Medium
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
9/16
10:09 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
Medium
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
9/16
09:43 am
acrv
Rating for ACRV
High
Report
Rating for ACRV
9/16
09:43 am
acrv
Rating for ACRV
High
Report
Rating for ACRV
9/16
09:22 am
acrv
Rating for ACRV
High
Report
Rating for ACRV
9/16
09:13 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $28.00 price target on the stock, up previously from $25.00.
High
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $28.00 price target on the stock, up previously from $25.00.
9/16
08:48 am
acrv
Rating for ACRV
High
Report
Rating for ACRV
9/16
08:48 am
acrv
Rating for ACRV
High
Report
Rating for ACRV
9/16
08:03 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
High
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
9/16
06:56 am
acrv
Acrivon Therapeutics upgraded to Buy on cancer data at Ladenburg
High
Report
Acrivon Therapeutics upgraded to Buy on cancer data at Ladenburg